FDA grants Fast Track Designation to pamrevlumab for treatment of Duchenne muscular dystrophy

The designation for this first-in-class antibody that inhibits activity of connective tissue growth factor follows review of phase 2 data from single-arm trial in non-ambulatory patients and represents recognition that pamrevlumab has potential to address unmet medical need.

Source:

Biospace Inc.